Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 10/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | FBP1 | P09467 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495287 | 0.91 | PPARG (0.48) | PPARGALOX5AP | |
| SCHEMBL6487079 | 0.91 | PPARG (0.48) | PPARGALOX5APDCTPP1PDE2ALMNA | |
| SCHEMBL6488332 | 0.90 | PPARG (0.47) | PPARGALOX5APPDE2AFBP1 | |
| SCHEMBL6489066 | 0.89 | PPARG (0.37) | PPARGALOX5APDCTPP1THRBTHRA | |
| SCHEMBL6500673 | 0.86 | PPARG (0.49) | PPARGALOX5APPDE2ATHRBTHRA | |
| SCHEMBL6497461 | 0.86 | PPARG (0.49) | PPARGALOX5APTHRBTHRALMNA | |
| SCHEMBL6487701 | 0.85 | PPARG (0.49) | PPARGALOX5APPDE2ATHRBTHRA | |
| SCHEMBL6490405 | 0.84 | PPARG (0.48) | PPARGALOX5APPDE2A | |
| SCHEMBL6308646 | 0.84 | PPARG (0.56) | PPARGALOX5APDCTPP1PDE2ATHRB | |
| SCHEMBL6487612 | 0.84 | PPARG (0.51) | PPARGALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PPARG 233/4885ALOX5AP 4663/4885DCTPP1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.